Starpharma Holdings Independent Non-Executive Chairman Acquires 10% More Stock
Potential Starpharma Holdings Limited (ASX:SPL) shareholders may wish to note that the Independent Non-Executive Chairman, Robert Thomas, recently bought AU$200k worth of stock, paying AU$0.57 for each share. That's a very decent purchase to our minds and it grew their holding by a solid 10%.
Starpharma Holdings Insider Transactions Over The Last Year
In the last twelve months, the biggest single purchase by an insider was when insider Peter Cook bought AU$14m worth of shares at a price of AU$0.54 per share. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of AU$0.72. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive.
In the last twelve months Starpharma Holdings insiders were buying shares, but not selling. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
See our latest analysis for Starpharma Holdings
Starpharma Holdings is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying.
Insider Ownership
I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. It appears that Starpharma Holdings insiders own 19% of the company, worth about AU$66m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.
What Might The Insider Transactions At Starpharma Holdings Tell Us?
The recent insider purchases are heartening. We also take confidence from the longer term picture of insider transactions. But we don't feel the same about the fact the company is making losses. When combined with notable insider ownership, these factors suggest Starpharma Holdings insiders are well aligned, and that they may think the share price is too low. Of course, the future is what matters most. So if you are interested in Starpharma Holdings, you should check out this free report on analyst forecasts for the company.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.